From: Tumor immunogenomic signatures improve a prognostic model of melanoma survival
Model | Covariate | TMB High (N = 220) | TMB Low (N = 58) | ||||
---|---|---|---|---|---|---|---|
HR (95% CI) | Covariate P (Wald) | Model P (log-rank) | HR (95% CI) | Covariate P (Wald) | Model P (log-rank) | ||
Age + Stage + MacReg | Age | 1.02 (1.01–1.04) | 2.17E−03 | 9.70E−07 | 1.02 (0.99–1.05) | 0.23 | 0.07 |
Stage | 1.89 (1.20–2.97) | 5.74E−03 | 1.31 (0.66–2.61) | 0.44 | |||
MacReg | 0.64 (0.49–0.84) | 1.19E−03 | 0.65 (0.44–0.97) | 3.26E−02 | |||
Age + Stage + IFNγRes | Age | 1.03 (1.01–1.04) | 6.50E−04 | 4.40E−08 | 1.02 (0.99–1.05) | 0.21 | 0.32 |
Stage | 2.11 (1.34–3.33) | 1.36E−03 | 1.22 (0.61–2.45) | 0.57 | |||
IFNγRes | 0.61 (0.48–0.77) | 4.39E−05 | 0.83 (0.58–1.19) | 0.31 | |||
Age + Stage + MacReg + IFNγRes | Age | 1.02 (1.01–1.04) | 1.42E−03 | 6.60E-08 | 1.02 (0.99–1.05) | 0.20 | 0.11 |
Stage | 2.05 (1.30–3.25) | 2.06E-03 | 1.42 (0.69–2.90) | 0.34 | |||
MacReg | 0.83 (0.59–1.16) | 0.27 | 0.56 (0.32–0.96) | 3.43E-02 | |||
IFNγRes | 0.67 (0.50–0.90) | 7.75E-03 | 1.22 (0.75–1.97) | 0.42 |